c

|  |
| --- |
| **Pharmacy and Therapeutics Committee** Virtual MeetingJanuary 24, 202412:00 PM - 5:00 PM |
| **Zoom Registration Link -** [**https://ahcccs.zoom.us/webinar/register/WN\_rm-o36stQ5uEu\_rS\_oCKUA**](https://ahcccs.zoom.us/webinar/register/WN_rm-o36stQ5uEu_rS_oCKUA) |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:10 PM** | **Minutes Review and Vote - P&T October 25, 2023:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:15 PM** | **Nineteen Non-Supplemental Rebate Drug Class:** Clinical review by Hind Douiki, PharmD, Magellan1. **Androgenic Agents**
	1. Public Testimony: None
2. **Antidepressants, Other**
	1. Public Testimony: None
3. **Antidepressants, SSRIs**
	1. Public Testimony: None
4. **Antivirals, Topical**
	1. Public Testimony: None
5. **Bone Resorption Suppression and Related Agents**
	1. Public Testimony: None
6. **Bronchodilators, Beta Agonists**
	1. Public Testimony: None
7. **Colony Stimulating Factors**
	1. Public Testimony: None
8. **Enzyme Replacement Products, Gaucher Disease**
	1. Oral Public Testimony: None
	2. Written Public Testimony:
		1. Aviva Rosenberg
9. **Erythropoiesis Stimulating Proteins**
	1. Public Testimony: None
10. **Hypoglycemics, Alpha Glucosidase Inhibitors**
	1. Oral Public Testimony: None
11. **Hypoglycemics, Metformins**
	1. Public Testimony: None
12. **Hypoglycemics, SGLT2s**
	1. Public Testimony: None
13. **Immunoglobulins**
	1. Oral Public Testimony: None
	2. Written Public Testimony:
		1. Matthew Prentice
14. **Oncology, Oral - Hematologics**
	1. Public Testimony: None
15. **Ophthalmics, Anti-inflammatory/Immunomodulators**
	1. Public Testimony: None
16. **Oral and Inhaled Pulmonary Arterial Hypertension Agents**
	1. Oral Public Testimony:
		1. Naomi Habib
		2. Debby Dunaway
17. **Otic Antibiotics**
	1. Public Testimony: None
18. **Thrombopoiesis Stimulating Agents**
	1. Public Testimony: None
19. **Ulcerative Colitis**
	1. Public Testimony: None
 |
|  |  |
| **2:00 PM** | **New Drug Reviews: Hind Douiki,** PharmD, Magellan1. Bimzelx - Bimekizumab
2. Daybue - Trofinetide
3. Jesduvroq - Daprodustat
4. Omvoh - Mirikizumab
5. Skyclarys - Omaveloxolone
	1. Oral Public Testimony:
		1. Elizabeth Mucklow
		2. Michael Wolfson
		3. Lynda Finch
	2. Written Public Testimony:
		1. Jen Farmer
6. Velsipity - Etrasimod arginine
7. Zurzuvae - Zuranolone
	1. Oral Public Testimony:
		1. Lynda Finch
	2. Written Public Testimony:
		1. Cindy Lee Herrick
		2. Carmen Koiscek
 |
|  **2:45 PM** | **Break & Executive Session:** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:15 PM** | **Public Therapeutic Class Votes:** Hind Douiki, PharmD, Magellan |
| **4:45 PM** | **Biosimilar Update: Suzi Berman** |
| **4:50 PM** | **Meeting Adjournment****Future Meeting Dates:** May 21, 2024 October 15, 2024January 25, 2025 |